Abstract:We purified a 120-kDa novel glycoprotein from human plasma and named it IHRP (inter-alpha-trypsin inhibitor family heavy chain-related protein) because of its sequence similarity to the heavy chains of the inter-alpha-trypsin inhibitor (ITI) family.1) IHRP was certified as the identical protein with PK-120 which was purified as a plasma kallikreinsensitive protein from human plasma.2) The ITI family includes ITI, pre-alpha-trypsin inhibitor and H2-bikunin. [3][4][5] All of them have the unique structures, i.e.… Show more
“…Of 18 identified proteins, one up regulated ITIH4 and one down regulated protein A2HSG in plasma of RA patients, were selected for further validation by immunobloting as these are known to be associated with inflammation [23], [24]. Since the enrichment of plasma glycoproteins by jacalin chromatography may not reflect the actual difference in the expression of the protein, the expression levels of A2HSG and ITIH4 were checked in plasma without jacalin enrichment by Western blotting (Figure 2A, C).…”
Glycosylation studies of plasma proteins can reveal information about the onset and progression of diseases, where in the glycan biosynthetic pathways are disturbed as in rheumatoid arthritis (RA). The present study was focused on analysis of O-linked glycoproteins of plasma in RA patients. Two dimensional gel electrophoresis of jacalin bound plasma of RA patients revealed a number of differentially expressed protein spots as compared to healthy controls. Eighteen protein spots were found to have statistically significant (p<0.05) difference in their expression level from four sets of gels and were identified by MALDI-TOF MS. Most of the identified proteins were predicted to be O-glycosylated proteins by Net–O-Gly 3.1 algorithm. Among these the alpha 2HS glycoprotein (A2HSG) was found to be down regulated whereas inter alpha trypsin inhibitor H4 (ITIH4) was up regulated and this was validated by Western blotting. The glycosylation studies showed the reduced N-linked sialylation of A2HSG in RA patients. Altered glycoprotein expression and functional as well as structural studies of glycans might help in the diagnosis of RA and understanding the disease pathogenesis.
“…Of 18 identified proteins, one up regulated ITIH4 and one down regulated protein A2HSG in plasma of RA patients, were selected for further validation by immunobloting as these are known to be associated with inflammation [23], [24]. Since the enrichment of plasma glycoproteins by jacalin chromatography may not reflect the actual difference in the expression of the protein, the expression levels of A2HSG and ITIH4 were checked in plasma without jacalin enrichment by Western blotting (Figure 2A, C).…”
Glycosylation studies of plasma proteins can reveal information about the onset and progression of diseases, where in the glycan biosynthetic pathways are disturbed as in rheumatoid arthritis (RA). The present study was focused on analysis of O-linked glycoproteins of plasma in RA patients. Two dimensional gel electrophoresis of jacalin bound plasma of RA patients revealed a number of differentially expressed protein spots as compared to healthy controls. Eighteen protein spots were found to have statistically significant (p<0.05) difference in their expression level from four sets of gels and were identified by MALDI-TOF MS. Most of the identified proteins were predicted to be O-glycosylated proteins by Net–O-Gly 3.1 algorithm. Among these the alpha 2HS glycoprotein (A2HSG) was found to be down regulated whereas inter alpha trypsin inhibitor H4 (ITIH4) was up regulated and this was validated by Western blotting. The glycosylation studies showed the reduced N-linked sialylation of A2HSG in RA patients. Altered glycoprotein expression and functional as well as structural studies of glycans might help in the diagnosis of RA and understanding the disease pathogenesis.
“…All peptide antibodies above were purified by both protein-A and affinity chromatography (Pierce Biotechnology). Both anti-ITIH4 rabbit antiserum (antiserum) and anti-ITIH4 mouse monoclonal antibody (1A4) were prepared by Dr. N.H. ChoiMiura (3,5 ). Antibody 1A4 recognizes an epitope located on the C-terminal M r 35 000 fragment of ITIH4.…”
Section: Antibodies To Human Itih4mentioning
confidence: 99%
“…Inter-␣-trypsin inhibitor heavy chain 4 (ITIH4) 5 is a plasma glycoprotein with a relative molecular mass of 120 000 that is expressed mainly in liver and that acts as an acute-phase protein in several species (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). Unlike other members of the inter-␣-trypsin inhibitor family (12,13 ), ITIH4 is present in plasma as a single-chain protein because its COOH terminus lacks the consensus sequence (DPHFII) for bikunin assembly through the glycosaminoglycan bridges (2,3,(12)(13)(14).…”
Background: Several proteolytically derived fragments from the proline-rich region (PRR) of human inter-␣-trypsin inhibitor heavy chain 4 (ITIH4) have been identified by surface-enhanced or matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS or MALDI-TOF-MS) as potential disease markers. Methods: Previously, we developed a SELDI-based immunoassay that can simultaneously distinguish and quantify multiple isoforms/variants of a protein/peptide of interest. In this study, we used this high-throughput approach to quantify and characterize the extensive fragmentation within the PRR of human serum ITIH4 and determined its association with different disease conditions. The ITIH4-related fragments were first immunocaptured by use of beads coupled with peptidespecific antibodies. The eluates were then studied by SELDI-TOF-MS. In addition, freshly collected and immediately processed serum and plasma samples were used to analyze the ex vivo stability of these ITIH4 fragments. Results: Human serum ITIH4 was shown to be extensively proteolytically processed within the PRR, and its fragmentation patterns were closely associated with different disease conditions. Fragmentation patterns
“…5 ITIH4 circulates in human blood
at a concentration of approximately 100 μg/mL. 6 It is a positive acute phase protein regulated by IL-6
and implicated in liver development and regeneration. 7−11 ITIH4 can be cleaved by plasma kallikrein into two fragments that
undergo additional proteolytic processing into an 85 kDa N-terminal
fragment and a 35 kDa C-terminal fragment.…”
Inter-alpha-trypsin
inhibitor heavy chain H4 (ITIH4) is a 120 kDa acute-phase glycoprotein
produced primarily in the liver, secreted into the blood, and identified
in serum. ITIH4 is involved in liver development and stabilization
of the extracellular matrix (ECM), and its expression is altered in
liver disease. In this study, we aimed to characterize glycosylation
of recombinant and serum-derived ITIH4 using analytical mass spectrometry.
Recombinant ITIH4 was analyzed to optimize glycopeptide analyses,
followed by serum-derived ITIH4. First, we confirmed that the four
ITIH4 N-X-S/T sequons (N81, N207, N517, and N577) were glycosylated
by treating ITIH4 tryptic/GluC glycopeptides with PNGaseF in the presence
of 18O water. Next, we performed glycosidase-assisted LC–MS/MS
analysis of ITIH4 trypsin-GluC glycopeptides enriched via hydrophilic
interaction liquid chromatography to characterize ITIH4 N-glycoforms.
While microheterogeneity of N-glycoforms differed between ITIH4 protein
expressed in HEK293 cells and protein isolated from serum, occupancy
of N-glycosylation sites did not differ. A fifth N-glycosylation site
was discovered at N274 with the rare nonconsensus NVV motif. Site
N274 contained high-mannose N-linked glycans in both serum and recombinant
ITIH4. We also identified isoform-specific ITIH4 O-glycoforms and
documented that utilization of O-glycosylation sites on ITIH4 differed
between the cell line and serum.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.